PubMed:30994353 / 81-279
Annnotations
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T2 | 0-198 | Sentence | denotes | Oncogenic BRAF mutations contribute to the development of a number of cancers, and small-molecule BRAF inhibitors have been approved by the Food and Drug Administration (FDA) for anticancer therapy. |
T2 | 0-198 | Sentence | denotes | Oncogenic BRAF mutations contribute to the development of a number of cancers, and small-molecule BRAF inhibitors have been approved by the Food and Drug Administration (FDA) for anticancer therapy. |
pubmed-enju-pas
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
EnjuParser_T11 | 0-9 | JJ | denotes | Oncogenic |
EnjuParser_T12 | 10-14 | NN | denotes | BRAF |
EnjuParser_T13 | 15-24 | NNS | denotes | mutations |
EnjuParser_T14 | 25-35 | VBP | denotes | contribute |
EnjuParser_T15 | 36-38 | TO | denotes | to |
EnjuParser_T16 | 39-42 | DT | denotes | the |
EnjuParser_T17 | 43-54 | NN | denotes | development |
EnjuParser_T18 | 55-57 | IN | denotes | of |
EnjuParser_T19 | 58-59 | DT | denotes | a |
EnjuParser_T20 | 60-66 | NN | denotes | number |
EnjuParser_T21 | 67-69 | IN | denotes | of |
EnjuParser_T22 | 70-77 | NNS | denotes | cancers |
EnjuParser_T23 | 77-78 | -COMMA- | denotes | , |
EnjuParser_T24 | 79-82 | CC | denotes | and |
EnjuParser_T25 | 83-97 | JJ | denotes | small-molecule |
EnjuParser_T26 | 98-102 | NN | denotes | BRAF |
EnjuParser_T27 | 103-113 | NNS | denotes | inhibitors |
EnjuParser_T28 | 114-118 | VBP | denotes | have |
EnjuParser_T29 | 119-123 | VBN | denotes | been |
EnjuParser_T30 | 124-132 | VBN | denotes | approved |
EnjuParser_T31 | 133-135 | IN | denotes | by |
EnjuParser_T32 | 136-139 | DT | denotes | the |
EnjuParser_T33 | 140-144 | NNP | denotes | Food |
EnjuParser_T34 | 145-148 | CC | denotes | and |
EnjuParser_T35 | 149-153 | NNP | denotes | Drug |
EnjuParser_T36 | 154-168 | NNP | denotes | Administration |
EnjuParser_T37 | 169-170 | -LRB- | denotes | ( |
EnjuParser_T38 | 170-173 | NNP | denotes | FDA |
EnjuParser_T39 | 173-174 | -RRB- | denotes | ) |
EnjuParser_T40 | 175-178 | IN | denotes | for |
EnjuParser_T41 | 179-189 | JJ | denotes | anticancer |
EnjuParser_T42 | 190-197 | NN | denotes | therapy |
EnjuParser_R10 | EnjuParser_T13 | EnjuParser_T11 | arg1Of | mutations,Oncogenic |
EnjuParser_R11 | EnjuParser_T13 | EnjuParser_T12 | arg1Of | mutations,BRAF |
EnjuParser_R12 | EnjuParser_T13 | EnjuParser_T14 | arg1Of | mutations,contribute |
EnjuParser_R13 | EnjuParser_T14 | EnjuParser_T15 | arg1Of | contribute,to |
EnjuParser_R14 | EnjuParser_T17 | EnjuParser_T15 | arg2Of | development,to |
EnjuParser_R15 | EnjuParser_T17 | EnjuParser_T16 | arg1Of | development,the |
EnjuParser_R16 | EnjuParser_T17 | EnjuParser_T18 | arg1Of | development,of |
EnjuParser_R17 | EnjuParser_T20 | EnjuParser_T18 | arg2Of | number,of |
EnjuParser_R18 | EnjuParser_T20 | EnjuParser_T19 | arg1Of | number,a |
EnjuParser_R19 | EnjuParser_T20 | EnjuParser_T21 | arg1Of | number,of |
EnjuParser_R20 | EnjuParser_T22 | EnjuParser_T21 | arg2Of | cancers,of |
EnjuParser_R21 | EnjuParser_T24 | EnjuParser_T23 | arg1Of | and,"," |
EnjuParser_R22 | EnjuParser_T14 | EnjuParser_T24 | arg1Of | contribute,and |
EnjuParser_R23 | EnjuParser_T30 | EnjuParser_T24 | arg2Of | approved,and |
EnjuParser_R24 | EnjuParser_T27 | EnjuParser_T25 | arg1Of | inhibitors,small-molecule |
EnjuParser_R25 | EnjuParser_T27 | EnjuParser_T26 | arg1Of | inhibitors,BRAF |
EnjuParser_R26 | EnjuParser_T27 | EnjuParser_T28 | arg1Of | inhibitors,have |
EnjuParser_R27 | EnjuParser_T30 | EnjuParser_T28 | arg2Of | approved,have |
EnjuParser_R28 | EnjuParser_T27 | EnjuParser_T29 | arg1Of | inhibitors,been |
EnjuParser_R29 | EnjuParser_T30 | EnjuParser_T29 | arg2Of | approved,been |
EnjuParser_R30 | EnjuParser_T34 | EnjuParser_T30 | arg1Of | and,approved |
EnjuParser_R31 | EnjuParser_T27 | EnjuParser_T30 | arg2Of | inhibitors,approved |
EnjuParser_R32 | EnjuParser_T34 | EnjuParser_T31 | arg2Of | and,by |
EnjuParser_R33 | EnjuParser_T34 | EnjuParser_T32 | arg1Of | and,the |
EnjuParser_R34 | EnjuParser_T33 | EnjuParser_T34 | arg1Of | Food,and |
EnjuParser_R35 | EnjuParser_T36 | EnjuParser_T34 | arg2Of | Administration,and |
EnjuParser_R36 | EnjuParser_T36 | EnjuParser_T35 | arg1Of | Administration,Drug |
EnjuParser_R37 | EnjuParser_T34 | EnjuParser_T37 | arg1Of | and,( |
EnjuParser_R38 | EnjuParser_T38 | EnjuParser_T37 | arg2Of | FDA,( |
EnjuParser_R39 | EnjuParser_T39 | EnjuParser_T37 | arg3Of | ),( |
EnjuParser_R40 | EnjuParser_T34 | EnjuParser_T40 | arg1Of | and,for |
EnjuParser_R41 | EnjuParser_T42 | EnjuParser_T40 | arg2Of | therapy,for |
EnjuParser_R42 | EnjuParser_T42 | EnjuParser_T41 | arg1Of | therapy,anticancer |